clinical trial · NCT07223047
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb·phase2·recruiting·n = 252
Advanced Solid MalignanciesNon-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)BMS-986523GemcitabineNab-PaclitaxelCetuximabPembrolizumab
brief summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
started
Nov 25, 2025
primary completion
Oct 13, 2028
completion
Oct 13, 2028
last updated
Apr 13, 2026
official title
A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol